Yamashita Yo-Ichi, Imai Katsunori, Mima Kosuke, Nakagawa Shigeki, Hashimoto Daisuke, Chikamoto Akira, Baba Hideo
Department of Gastroenterological Surgery, Graduate School of Medical Sciences Kumamoto University Kumamoto Japan.
Hepatol Commun. 2017 Jun 28;1(6):494-500. doi: 10.1002/hep4.1064. eCollection 2017 Aug.
Idiosyncratic drug-induced liver injury (iDILI) is a rare adverse drug reaction that occasionally leads to acute liver failure or even death. An aging population that uses more drugs, a constant influx of newly developed drugs, and a growing risk from herbal and dietary supplements of uncertain quality can lead to an increase in iDILI. Antimicrobials, central nervous system agents, and herbal and dietary supplements are the most common causes of iDILI in developed countries. iDILI is still a diagnosis of exclusion, and thus careful history taking and thorough work-ups for competing etiologies, such as acute viral hepatitis, autoimmune hepatitis, and others, are essential. The pathogenesis of iDILI is not clear and includes a mix of host reactions, drug metabolites, and environmental factors. Immediate cessation of the suspected offending drug is key to preventing or minimizing progressive damage. No definitive therapies for iDILI are available, and the treatments remain largely supportive. ( 2017;1:494-500).
特异质性药物性肝损伤(iDILI)是一种罕见的药物不良反应,偶尔会导致急性肝衰竭甚至死亡。使用更多药物的老龄化人口、新研发药物的不断涌入,以及质量不确定的草药和膳食补充剂带来的风险增加,都可能导致iDILI病例增多。在发达国家,抗菌药物、中枢神经系统药物以及草药和膳食补充剂是iDILI最常见的病因。iDILI仍然是一种排除性诊断,因此仔细询问病史并对诸如急性病毒性肝炎、自身免疫性肝炎等其他可能病因进行全面检查至关重要。iDILI的发病机制尚不清楚,包括宿主反应、药物代谢产物和环境因素的综合作用。立即停用可疑的致病药物是预防或减少进行性损害的关键。目前尚无针对iDILI的确切治疗方法,治疗主要仍是支持性的。(2017;1:494 - 500)